{"id":"rituximab-monotherapy","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Infusion reactions"},{"rate":"20-40","effect":"Infections"},{"rate":"10-30","effect":"Cytopenias (anemia, thrombocytopenia, neutropenia)"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rituximab targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers multiple mechanisms of B cell death including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This results in rapid depletion of B cells, reducing autoimmune and malignant B cell populations.","oneSentence":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:30.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"},{"name":"Rheumatoid arthritis"},{"name":"Granulomatosis with polyangiitis"},{"name":"Microscopic polyangiitis"}]},"trialDetails":[{"nctId":"NCT06149286","phase":"PHASE3","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-28","conditions":"Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)","enrollment":470},{"nctId":"NCT07226843","phase":"PHASE1","title":"A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02","conditions":"Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma","enrollment":360},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":"CLL, Chronic Lymphocytic Leukemia","enrollment":250},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07104032","phase":"PHASE3","title":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-03","conditions":"Relapsed/Refractory Primary Central Nervous System Lymphoma","enrollment":132},{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT07222631","phase":"PHASE1, PHASE2","title":"SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-02-18","conditions":"Non Hodgkin Lymphoma, Solid Tumor","enrollment":48},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":"Chronic Lymphocytic Leukemia","enrollment":42},{"nctId":"NCT03986034","phase":"PHASE2","title":"Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2019-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":75},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT07415980","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Double Expressor DLBCL","enrollment":68},{"nctId":"NCT02158091","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-06-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT04669171","phase":"PHASE1, PHASE2","title":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Enterome","startDate":"2021-07-05","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":80},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT07355699","phase":"PHASE4","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-25","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":88},{"nctId":"NCT05735834","phase":"PHASE3","title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2024-05-21","conditions":"Splenic Marginal Zone Lymphoma","enrollment":122},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":150},{"nctId":"NCT04843904","phase":"PHASE1","title":"Safe Accelerated Venetoclax Escalation in CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-14","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04661007","phase":"PHASE1, PHASE2","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences Japan GK","startDate":"2020-12-15","conditions":"Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":72},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT06265220","phase":"PHASE1","title":"AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2024-04-03","conditions":"Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus","enrollment":51},{"nctId":"NCT04743739","phase":"PHASE3","title":"Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN","status":"TERMINATED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":12},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT04947319","phase":"PHASE2","title":"Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-12-29","conditions":"Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma","enrollment":119},{"nctId":"NCT04002297","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2019-08-20","conditions":"Mantle Cell Lymphoma; Non-Hodgkin Lymphoma","enrollment":510},{"nctId":"NCT05728658","phase":"PHASE1","title":"The Study of ICP-248 in Patients With Mature B-cell Malignancies","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2023-03-09","conditions":"Hematological Malignancies","enrollment":191},{"nctId":"NCT04433182","phase":"PHASE2","title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-08-18","conditions":"Diffuse Large B-cell Lymphoma","enrollment":37},{"nctId":"NCT07073833","phase":"PHASE1","title":"The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","startDate":"2025-07-20","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT06351527","phase":"PHASE1","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies","status":"RECRUITING","sponsor":"InnoCare Pharma Inc.","startDate":"2024-04-23","conditions":"Mature B-cell Malignancies","enrollment":78},{"nctId":"NCT06700798","phase":"PHASE2","title":"Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial","status":"RECRUITING","sponsor":"Fei Li","startDate":"2024-12-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":90},{"nctId":"NCT04673617","phase":"PHASE1, PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":"Non Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT06119685","phase":"PHASE1, PHASE2","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","status":"RECRUITING","sponsor":"Indapta Therapeutics, INC.","startDate":"2023-10-25","conditions":"NHL, Multiple Myeloma, Blood Cancer","enrollment":128},{"nctId":"NCT04464798","phase":"PHASE1","title":"A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas","status":"TERMINATED","sponsor":"Celgene","startDate":"2020-11-11","conditions":"Lymphoma","enrollment":62},{"nctId":"NCT03492125","phase":"PHASE1, PHASE2","title":"A Study Of The Selective PKC-β Inhibitor MS- 553","status":"TERMINATED","sponsor":"MingSight Pharmaceuticals, Inc","startDate":"2018-05-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma","enrollment":60},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT03804372","phase":"PHASE2","title":"The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide","status":"TERMINATED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-07-07","conditions":"Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia","enrollment":5},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT05914662","phase":"PHASE2","title":"Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-15","conditions":"Waldenstrom Macroglobulinemia","enrollment":42},{"nctId":"NCT02157181","phase":"PHASE2","title":"Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab","status":"COMPLETED","sponsor":"Jurgen Barth","startDate":"2004-06","conditions":"Hairy Cell Leukemia (HCL)","enrollment":89},{"nctId":"NCT02594384","phase":"PHASE1","title":"A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"OrphAI Therapeutics","startDate":"2015-10","conditions":"Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic","enrollment":62},{"nctId":"NCT01199575","phase":"PHASE2","title":"Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2010-08","conditions":"Chronic Lymphocytic Leukemia, CLL","enrollment":30},{"nctId":"NCT04914741","phase":"PHASE1, PHASE2","title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-06-29","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":80},{"nctId":"NCT05718856","phase":"PHASE4","title":"TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-02-23","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":166},{"nctId":"NCT04915482","phase":"PHASE2, PHASE3","title":"TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-06-06","conditions":"Immune Thrombocytopenia (ITP), Autoantibodies, Evan Syndrome","enrollment":94},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT03934814","phase":"PHASE1","title":"Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma","status":"COMPLETED","sponsor":"I-Mab Biopharma US Limited","startDate":"2019-04-16","conditions":"Solid Tumor, Lymphoma","enrollment":98},{"nctId":"NCT06445257","phase":"NA","title":"A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL","status":"RECRUITING","sponsor":"Huai'an First People's Hospital","startDate":"2023-09-15","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02663518","phase":"PHASE1","title":"A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-01-28","conditions":"Hematologic Malignancies, Solid Tumor","enrollment":249},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT05514015","phase":"PHASE4","title":"Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-03-29","conditions":"Primary Membranous Nephropathy","enrollment":78},{"nctId":"NCT06289959","phase":"NA","title":"Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-02-25","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":30},{"nctId":"NCT03864419","phase":"PHASE1","title":"Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-10-24","conditions":"Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, Diffuse Large B-Cell Lymphoma","enrollment":18},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT02733042","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-11","conditions":"Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":106},{"nctId":"NCT04245722","phase":"PHASE1","title":"FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2020-03-19","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia","enrollment":98},{"nctId":"NCT04023071","phase":"PHASE1","title":"FT516 in Subjects With Advanced Hematologic Malignancies","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2019-10-04","conditions":"Acute Myelogenous Leukemia, B-cell Lymphoma","enrollment":72},{"nctId":"NCT02005471","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":389},{"nctId":"NCT05734794","phase":"PHASE3","title":"Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2023-02-09","conditions":"Nephrotic Syndrome in Children, Rituximab","enrollment":80},{"nctId":"NCT05508009","phase":"PHASE1, PHASE2","title":"Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor","status":"RECRUITING","sponsor":"Alice Bertaina","startDate":"2023-01-10","conditions":"SIOD, Cystinosis, FSGS","enrollment":12},{"nctId":"NCT01307605","phase":"PHASE2","title":"Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":154},{"nctId":"NCT04136756","phase":"PHASE1","title":"NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2019-10-07","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT04502706","phase":"PHASE1","title":"Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2020-11-17","conditions":"Non-hodgkin Lymphoma","enrollment":9},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT02914938","phase":"PHASE1","title":"A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"MEI Pharma, Inc.","startDate":"2016-10","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL)","enrollment":97},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT02752815","phase":"PHASE4","title":"Reduced Chemotherapy in Low Risk DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-06-14","conditions":"Diffuse Large B-cell Lymphoma","enrollment":290},{"nctId":"NCT02042391","phase":"PHASE2","title":"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","status":"COMPLETED","sponsor":"Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","startDate":"2015-02-03","conditions":"Posttransplant Lymphoproliferative Disorder","enrollment":60},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT05384743","phase":"PHASE3","title":"Rituximab Monotherapy for EBV-HLH and CAEBV","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2022-02-01","conditions":"Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection","enrollment":30},{"nctId":"NCT05379647","phase":"PHASE1","title":"Natural Killer (NK) Cell Therapy for B-Cell Malignancies","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-11-04","conditions":"B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT01587040","phase":"PHASE1, PHASE2","title":"Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07-20","conditions":"Neoplasm Malignant","enrollment":61},{"nctId":"NCT05287984","phase":"PHASE2","title":"Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-03-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed","enrollment":63},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT05050630","phase":"PHASE2","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2021-08-01","conditions":"Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed","enrollment":73},{"nctId":"NCT02631538","phase":"PHASE2","title":"Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-17","conditions":"Sjogren's Syndrome","enrollment":86},{"nctId":"NCT03304288","phase":"PHASE2","title":"The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2017-10-11","conditions":"Immune Thrombocytopenia","enrollment":168},{"nctId":"NCT04659434","phase":"PHASE2","title":"Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL","status":"UNKNOWN","sponsor":"Qian Wenbin","startDate":"2020-12-10","conditions":"Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":51},{"nctId":"NCT03023878","phase":"PHASE2","title":"Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-13","conditions":"High-risk Diffuse Large B-Cell Lymphoma","enrollment":47},{"nctId":"NCT01077518","phase":"PHASE3","title":"Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-26","conditions":"Lymphoma, Follicular","enrollment":346},{"nctId":"NCT00088530","phase":"PHASE3","title":"BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-07","conditions":"Lymphoma, Non-Hodgkin","enrollment":140},{"nctId":"NCT02162771","phase":"PHASE3","title":"To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-07-14","conditions":"Lymphoma, Follicular","enrollment":140},{"nctId":"NCT00909077","phase":"PHASE3","title":"The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2004-08","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":155},{"nctId":"NCT02453087","phase":"PHASE1","title":"A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":66},{"nctId":"NCT03980002","phase":"PHASE2","title":"A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-05-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT03349346","phase":"PHASE1","title":"Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2019-06","conditions":"Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":399,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rituximab Monotherapy","genericName":"Rituximab Monotherapy","companyName":"Beijing Friendship Hospital","companyId":"beijing-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody used as a binding agent to target the B-lymphocyte antigen CD20. It has been studied in clinical trials for various conditions, including Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, and Multiple Myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}